Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2015', provides an overview of the Varicella Zoster (HHV-3) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Varicella Zoster (HHV-3) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Varicella Zoster (HHV-3) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Varicella Zoster (HHV-3) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Varicella Zoster (HHV-3) Infections Overview 9
Therapeutics Development 10
Pipeline Products for Varicella Zoster (HHV-3) Infections - Overview 10
Pipeline Products for Varicella Zoster (HHV-3) Infections - Comparative Analysis 11
Varicella Zoster (HHV-3) Infections - Therapeutics under Development by Companies 12
Varicella Zoster (HHV-3) Infections - Therapeutics under Investigation by Universities/Institutes 14
Varicella Zoster (HHV-3) Infections - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Varicella Zoster (HHV-3) Infections - Products under Development by Companies 19
Varicella Zoster (HHV-3) Infections - Products under Investigation by Universities/Institutes 21
Varicella Zoster (HHV-3) Infections - Companies Involved in Therapeutics Development 22
Astellas Pharma Inc. 22
Beijing Minhai Biotechnology Co., Ltd 23
Beijing Tiantan Biological Products Co., Ltd. 24
China National Pharmaceutical Group Corporation 25
Chongqing Zhifei Biological Products Co., Ltd. 26
Epiphany Biosciences, Inc. 27
Foamix Pharmaceuticals Ltd. 28
GlaxoSmithKline plc 29
Green Cross Corporation 30
Merck & Co., Inc. 31
NAL Pharmaceuticals Ltd. 32
Sinovac Biotech Ltd. 33
SK Chemicals Co., Ltd. 34
Spider Biotech 35
Varicella Zoster (HHV-3) Infections - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
acyclovir - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
amenamevir - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
chickenpox vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
chickenpox vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
FV-100 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
GSK-1437173A - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
herpes zoster vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
HHV-3 vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
measles + mumps + rubella + varicella vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
measles + mumps + rubella + varicella vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
measles + rubella + varicella vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MG-1111 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
NAL-3221 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
NAL-3223 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
RKP-00156 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
sattabacin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SB-105A10 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
V-212 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
valomaciclovir stearate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
varicella vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
varicella vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Varicella Zoster (HHV-3) Infections - Recent Pipeline Updates 72
Varicella Zoster (HHV-3) Infections - Dormant Projects 77
Varicella Zoster (HHV-3) Infections - Discontinued Products 79
Varicella Zoster (HHV-3) Infections - Product Development Milestones 80
Featured News & Press Releases 80
Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN 80
Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint 80
Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant 81
Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles 81
Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles 82
Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster And Post-herpetic Neuralgia In Older US Population, Cohort Study Finds 82
Jul 18, 2012: Agenus Annnounces Intiation Of Phase III Clinical Trial Of GSK's Herpes Zoster Vaccine Candidate In Immunocompromised Patients 84
Jun 05, 2012: Kaiser Permanente Study Shows GSK's Zoster Lowers Short-Term Risk Of Shingles Recurrence 85
Dec 13, 2010: Inhibitex Reports Promising Top-Line Results From Phase II Shingles Trial With FV-100 86
Oct 15, 2010: Inhibitex Completes Enrollment In Phase II Clinical Trial Of FV-100 In Shingles Patients 87
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 88
Disclaimer 89

List of Tables

Number of Products under Development for Varicella Zoster (HHV-3) Infections, H1 2015 10
Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Varicella Zoster (HHV-3) Infections - Pipeline by Astellas Pharma Inc., H1 2015 22
Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 23
Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015 24
Varicella Zoster (HHV-3) Infections - Pipeline by China National Pharmaceutical Group Corporation, H1 2015 25
Varicella Zoster (HHV-3) Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015 26
Varicella Zoster (HHV-3) Infections - Pipeline by Epiphany Biosciences, Inc., H1 2015 27
Varicella Zoster (HHV-3) Infections - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 28
Varicella Zoster (HHV-3) Infections - Pipeline by GlaxoSmithKline plc, H1 2015 29
Varicella Zoster (HHV-3) Infections - Pipeline by Green Cross Corporation, H1 2015 30
Varicella Zoster (HHV-3) Infections - Pipeline by Merck & Co., Inc., H1 2015 31
Varicella Zoster (HHV-3) Infections - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 32
Varicella Zoster (HHV-3) Infections - Pipeline by Sinovac Biotech Ltd., H1 2015 33
Varicella Zoster (HHV-3) Infections - Pipeline by SK Chemicals Co., Ltd., H1 2015 34
Varicella Zoster (HHV-3) Infections - Pipeline by Spider Biotech, H1 2015 35
Assessment by Monotherapy Products, H1 2015 36
Assessment by Combination Products, H1 2015 37
Number of Products by Stage and Target, H1 2015 39
Number of Products by Stage and Mechanism of Action, H1 2015 41
Number of Products by Stage and Route of Administration, H1 2015 43
Number of Products by Stage and Molecule Type, H1 2015 45
Varicella Zoster (HHV-3) Infections Therapeutics - Recent Pipeline Updates, H1 2015 72
Varicella Zoster (HHV-3) Infections - Dormant Projects, H1 2015 77
Varicella Zoster (HHV-3) Infections - Dormant Projects (Contd..1), H1 2015 78
Varicella Zoster (HHV-3) Infections - Discontinued Products, H1 2015 79